comparemela.com

Latest Breaking News On - Elsevier ltd - Page 34 : comparemela.com

BRIGHT-4 trial: bivalirudin strikes back

We read with great interest the study by Yi Li and colleagues1 that reports the comparison of bivalirudin plus high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction having percutaneous coronary intervention. The authors conclude that bivalirudin reduced the 30-day composite rate of all-cause mortality or Bleeding Academic Research Consortium types 3–5 major bleeding compared with heparin. This large, well conducted study provides new data to the debate regarding the appropriate anticoagulation for these patients.

Electronic nicotine delivery systems: pragmatism or expectancy? – Authors reply

Alain Braillon and Adam Edward Lang raise important questions about e-cigarettes and harm reduction in response to our Comment.1 Here, we explain why a pragmatic approach to maximising e-cigarettes’ harm reduction potential is important.

The needs of children born preterm are too often overlooked – Authors reply

We thank Eilis Kennedy and Guy Skinner for highlighting the importance of the new WHO recommendations for the care of preterm or low birthweight infants with particular attention to immediate kangaroo mother care and family involvement and support and for pointing out some key challenges to ensuring that the new recommendations are carried out and achieve their potential benefits.1 Challenges in supporting families in the care of preterm infants in neonatal intensive care units have been well documented.

Unsuccessful ban on gutkha and need for tobacco control in India

In India, the use of smokeless tobacco, including gutkha, is a prevalent and dangerous practice that poses serious health risks, especially for oral cancer. Despite being banned by Indian states since 2012, gutkha remains widely used and available.1 Gutkha is a mixture of areca nuts, slaked lime, catechu, tobacco, added flavourings, and sweeteners.2 The ban on gutkha aimed to control addiction rates and adverse effects on the oral mucosa. However, companies producing gutkha have found ways to circumvent the ban by producing pan masala (a non-tobacco product containing areca nuts, slaked lime, catechu, and seasonings) under the same brand name, with tobacco provided separately in a packet for free, allowing users to prepare their own gutkha.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.